secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001641172-25-011962
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries
--------------------------------------------------------------------------------

- Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
- Pharma 1 targets mid-2025 regulatory submission in UAE; must file within 3 months of agreement.
- Consideration includes upfront payment, regulatory milestones, and sales-based milestones; supply at cost-plus.
- SOLOSEC is FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.
- Expands existing Evofem-Pharma 1 partnership beyond PHEXXI to SOLOSEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225011962/0001641172-25-011962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225011962/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer